Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | AHR | P35869 | 3/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | PRKCA | P17252 | 3/20 | 0.50 |
| ▸ | CDK4 | P11802 | 2/20 | 0.50 |
| ▸ | CCND1 | P24385 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | PRKCB | P05771 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | PRKACG | P22612 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24115417 | 0.86 | MEN1 (0.55) | MEN1MAPTKMT2AAHRCHEK1 | |
| SCHEMBL21203060 | 0.84 | MEN1 (0.56) | MEN1MAPTKMT2AAHRCHEK1 | |
| SCHEMBL29440653 | 0.83 | AHR (1.00) | MEN1MAPTKMT2AAHRCHEK1 | |
| SCHEMBL528520 | 0.83 | AHR (1.00) | MEN1MAPTKMT2AAHRCHEK1 | |
| SCHEMBL4733891 | 0.79 | MEN1 (0.55) | MEN1MAPTKMT2AAHRCHEK1 | |
| SCHEMBL14519076 | 0.77 | GSK3B (0.53) | MEN1MAPTKMT2AAHRGSK3B | |
| SCHEMBL22779895 | 0.77 | AHR (0.49) | MEN1MAPTKMT2AAHRCHEK1 | |
| SCHEMBL20865251 | 0.76 | EGFR (0.51) | MEN1MAPTKMT2AAHRPRKCA | |
| SCHEMBL12766730 | 0.76 | MAPT (0.51) | MEN1MAPTKMT2AAHRCHEK1 | |
| SCHEMBL12219428 | 0.75 | CHEK1 (0.65) | MEN1MAPTKMT2AAHRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220275331-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | LIFE TECHNOLOGIES AS (NO) | 2022-09-01 | — | — | US | disclosed |
| EP-2598138-B1 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | UNIV BOSTON (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190225683-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| US-10314810-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-06-11 | — | — | US | disclosed |
| US-10258600-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3265816-B1 | DETECTION METHOD AND KIT | EUROPEAN UNION REPRESENTED BY THE EUROPEAN COMMISSION (BE) | 2018-11-28 | — | — | EP | disclosed |
| EP-3368659-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | Life Technologies AS (NO) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017083809-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017072251-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | LIFE TECHNOLOGIES AS (NO) | 2017-05-04 | — | — | WO | disclosed |
| US-20160175278-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-06-23 | — | — | US | disclosed |
| US-20130281525-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2598138-A2 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | Trustees of Boston University (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015914-A2 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258600-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | AHR, ARNT, AIPL1 | MEN1 4766/4885MAPT 4764/4885KMT2A 1395/4885 |
| US-20130281525-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | AHR, ARNT, AIPL1 | MEN1 4766/4885MAPT 4764/4885KMT2A 1395/4885 |
| US-20160175278-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | AHR, ARNT, AIPL1 | MEN1 4766/4885MAPT 4764/4885KMT2A 1395/4885 |
| US-20190225683-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | RORC, OXA1L, CX3CR1 | MEN1 4877/4885MAPT 1568/4885KMT2A 4426/4885 |
| US-10314810-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | AHR, ARNT, AIPL1 | MEN1 4766/4885MAPT 4764/4885KMT2A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.